DRKS00009691CompletedNot Applicable
HepNet patient registry- secondary prevention of hepatic encephalopathy - HE-Register
Deutsche Leberstiftung0 sites115 target enrollmentStarted: November 23, 2015Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 115
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 Years to one (—)
- Sex
- All
Inclusion Criteria
- •Patients (> 18 years) with symptomatic hepatic encephalopathy, which required hospitalization in the last 3 months
Exclusion Criteria
- •hospitalization at baseline.
- •max. 50 patients will be enrolled with MELD> 20 (Should this have a strong negative impact on the recruitment, the number can be increased).
Investigators
Similar Trials
Active, not recruiting
Phase 1
PROLONGSTEM is a long term follow-up study of all the patients who have received at least one infusion of HepaStemThis study will include all patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HALPC during a previous interventional clinical study conducted by Promethera Biosciences or Promethera Therapeutics including patients suffering from urea cycle disorders (UCD), Crigler-Najjar (CN) and Fibroinflammatory liver diseases.MedDRA version: 20.1Level: LLTClassification code: 10021601Term: Inborn error of metabolism NOS Class: 10010331MedDRA version: 20.0Level: LLTClassification code: 10008954Term: Chronic liver disease and cirrhosis Class: 10019805MedDRA version: 21.1Level: LLTClassification code: 10013373Term: Disorders of urea cycle metabolism Class: 10010331MedDRA version: 20.1Level: LLTClassification code: 10049844Term: Acute liver failure Class: 10019805CTIS2022-500251-22-00Cellaïon SA68
Completed
Not Applicable
A national registration survey of patients with hypertrophic cardiomyopathy in JapaHypertrophic cardiomyopathyJPRN-UMIN000024407Kochi Medical School, Kochi University1,485
Recruiting
Not Applicable
Clinical registry for patients with primary an recurrent rectal cancerC20Malignant neoplasm of rectumDRKS00015005niversitätsklinikum Freiburg999,999
Active, not recruiting
Phase 1
PROLONGSTEM is a long term follow-up study of all the patients who have received at least one infusion of HepaStemThis study will include all patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Biosciences including patients suffering from urea cycle disorders (UCD), Crigler-Najjar (CN) and Fibro-inflammatory liver diseasesMedDRA version: 20.1 Level: LLT Classification code 10021601 Term: Inborn error of metabolism NOS System Organ Class: 100000004850MedDRA version: 20.0 Level: LLT Classification code 10008954 Term: Chronic liver disease and cirrhosis System Organ Class: 100000004871MedDRA version: 20.1 Level: LLT Classification code 10049844 Term: Acute liver failure System Organ Class: 100000004871MedDRA version: 20.1 Level: LLT Classification code 10013373 Term: Disorders of urea cycle metabolism System Organ Class: 200000003094EUCTR2017-003989-27-GBPromethera Biosciences22
Not yet recruiting
Not Applicable
Promoting hospital-hospital referral system for hepatitis C virus carriers to hepatologist: multi-center studyHepatitis C virus carriersJPRN-UMIN000029755Kumamoto University2,000